Disease Spotlight: Prostate Cancer

 

Study Assesses PET Agent for Detecting Pelvic Lymph Node Metastases in Patients with Prostate Cancer

December 06, 2022

For patients recently diagnosed with prostate cancer, the emerging positron emission tomography (PET) agent 18F-rhPSMA-7.3 reportedly has a 96 percent specificity rate for detecting pelvic lymph node metastases, according to Phase 3 study results recently presented at the 22nd Annual Scientific Meeting of the Society of Urologic Oncology (SUO).

Can MRI-Based Prostate Cancer Screening be a Viable Alternative to PSA Testing?

December 01, 2022

In what may be the first study to assess the effectiveness of biparametric magnetic resonance imaging (MRI) for prostate cancer screening in a large cohort, researchers found that MRI screening had a significantly lower false positive rate and significantly higher positive predictive values (PPVs) than prostate-specific antigen (PSA)-based screening.

Radiotherapy for Prostate Cancer: Study Says MRI Guidance Significantly Reduces GU and GI Toxicities

October 28, 2022

For patients undergoing stereotactic body radiotherapy (SBRT) for prostate cancer, the acute genitourinary (GU) toxicity rate associated with the procedure was 19 percent lower with magnetic resonance imaging (MRI) guidance in comparison to computed tomography (CT) guidance, according to new research presented recently at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

Could an Emerging PSMA/PET Imaging Agent Improve the Detection of Recurrent Prostate Cancer?

October 25, 2022

In a recent video interview from the American Society for Radiation Oncology (ASTRO) Annual Meeting, Benjamin Lowentritt, MD discussed the challenges of conventional imaging in diagnosing prostate cancer recurrence and the potential of an emerging high affinity, radiohybrid prostate-specific membrane antigen/positron emission tomography (PSMA/PET) imaging agent.

Study Suggests Shorter Duration of Radiation Therapy is Effective for High-Risk Prostate Cancer

October 24, 2022

Five weeks of radiation therapy is just as effective as eight weeks of radiation treatment for men with high-risk prostate cancer, according to new research presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

Could a New PSMA-Derived Radiomics Model Help Detect Intraprostatic Lesions on PET/CT?

October 13, 2022

An emerging radiomics model, derived from 68Ga-PSMA-11 PET, reportedly offers a superior area under the curve (AUC) and higher sensitivity than radiologist assessment in detecting intraprostatic lesions via positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer.